Spero Therapeutics director granted RSUs, options
Spero Therapeutics director Frank E. Thomas received new equity awards as part of his compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Spero Therapeutics director Frank E. Thomas received new equity awards as part of his compensation. He was granted 10,000 shares of common stock in the form of restricted stock units, which vest on June 23, 2027, as long as he continues serving through that date.
He was also granted options to buy 20,000 shares of common stock at an exercise price of $2.15 per share. These options vest and become exercisable in full on June 23, 2027, subject to his continued service as a director. After the stock grant, he holds 85,000 common shares directly.
Insider Trade Summary
Grant/Award: 30,000 shares
Grant/Award
2 txns
Insider
THOMAS FRANK E
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 20,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 10,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 20,000 contracts (Direct);
Common Stock — 85,000 shares (Direct)
Footnotes (2)
- F1. Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date.
- F2. The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date.
Key Figures
RSU grant: 10,000 shares
Option grant size: 20,000 shares
Option exercise price: $2.15 per share
+3 more
6 metrics
RSU grant
10,000 shares
Restricted stock units vesting June 23, 2027
Option grant size
20,000 shares
Stock options granted June 23, 2026
Option exercise price
$2.15 per share
Stock Option (right to buy) grant
Option expiration
June 23, 2036
Expiration date of granted stock options
Shares after transaction
85,000 shares
Common stock held directly after RSU grant
Transactions coded A
2 acquisitions
Both entries classified as grant/award acquisitions
Key Terms
restricted stock units ("RSUs"), Stock Option (right to buy), vest, exercise price
4 terms
restricted stock units ("RSUs") financial
"Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (right to buy) financial
"Stock Option (right to buy) with 20,000.0000 shares at an exercise price of 2.1500."
vest financial
"The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Spero Therapeutics (SPRO) director Frank E. Thomas receive in this Form 4?
He received equity-based compensation consisting of restricted stock units and stock options. The filing reports 10,000 RSUs and options for 20,000 shares, both tied to continued service and vesting on June 23, 2027.
What are the key terms of the Spero Therapeutics stock options granted in this filing?
The options cover 20,000 shares of common stock at a $2.15 exercise price. They vest and become fully exercisable on June 23, 2027, conditioned on the director’s continued service on the board through that date.
When do the Spero Therapeutics RSUs and options reported here vest?
Both the RSUs and the stock options vest on June 23, 2027. Vesting is contingent on the reporting person’s continued service as a director through that date, as described in the footnotes to the Form 4.
Is the Form 4 for Spero Therapeutics a buy or sell by the director?
The Form 4 reflects equity awards, not market buys or sells. It reports acquisitions coded as grants or awards of 10,000 RSUs and options on 20,000 shares, which are part of the director’s compensation package.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates